

CD274

Human anti-PD-L1 (Avelumab) mAb

Catalog No.	CSB117A CSB117B	Quantity:	200 µg 1.0 mg
Alternate Names:	MSB-0010718C, MSB0010682, Bavencio		
Description:	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1), resulting in an increased CD8+ T cell immune response. Avelumab belongs to the group of immune checkpoint blockade cancer therapies, with potential antibody-dependent cell-mediated cytotoxicity. It is used for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	Q9NZQ7		
Source:	CHO cell line		
Isotype:	Human IgG1 lambda		
INN:	Avelumab		
Specificity:	Human PD-L1		
Biologic Activity:	Binds to PD-L1 and inhibits its binding to its receptor PD-1		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com